AU2020204427A1 — Drug eluting ocular implant
Assigned to Glaukos Corp · Expires 2020-07-23 · 6y expired
What this patent protects
An drug delivery ocular implant comprising: an outer shell having an open first end and a closed second end, the outer shell configured to contain at least one drug; a cap configured to be joined with the outer shell at the open first end to form an interior space, the cap havi…
USPTO Abstract
An drug delivery ocular implant comprising: an outer shell having an open first end and a closed second end, the outer shell configured to contain at least one drug; a cap configured to be joined with the outer shell at the open first end to form an interior space, the cap having at least one region of drug release, the at least one region of drug release comprising at least one orifice, a permeable or semi-permeable membrane or a coating within the interior space, wherein a permeability of the membrane or the coating is configured to at least partially control the rate of elution of the at least one drug through the at least one region of drug release to a region within an eye. 90 1/56 N N K1 N N N
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.